Superworth

Fortress Biotech price to book ratio FBIO

Market value divided by the book value of the company's net assets, since 2012.

Today, Oct 23, 2026
0.4×
10-year median
2.6×
Against its 10-year history
0th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.4× to 63.2×
Peer median
1.5×

Fortress Biotech's price to book ratio is 0.4× as of Oct 23, 2026.

That is below its ten-year median of 2.6×, lower than on 100% of days in the last ten years.

Over that time it ranged from 0.4× in Oct 2026 to 63.2× in Apr 2019.

The median for 9 large drugmakers of a similar size is 1.5×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far0.4×0.4×2.4×
20252.1×1.4×2.9×
20243.1×0.9×3.1×
20231.6×0.6×3.2×
20221.2×0.9×2.6×
20212.7×2.6×5.1×
20203.1×2.4×8.1×
20196.8×1.6×63.2×
20181.3×0.9×7.1×
20175.5×2.7×5.6×
20163.6×2.1×4.1×
20152.5×1.5×2.9×
20141.4×0.8×1.6×
20131.1×0.5×13.4×
20124.0×3.6×9.6×

Against its peers

Companies in Drug Manufacturers - General nearest Fortress Biotech's size, closest first, today.

CompanyPrice to book ratio
FBIOFortress Biotech0.4×
SPROSpero Therapeutics1.5×
LFVNLifevantage2.2×
ATNMActinium Pharmaceuticals1.6×
NATRNatures Sunshine Products1.3×
ARVNArvinas0.8×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
Peer median1.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Fortress Biotech

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.